Yiming Enko-B (01541) quickly rose by more than 20%. As of press release, it rose 20.27% to HK$17.8, with a turnover of HK$3.31 million.
The Zhitong Finance App learned that Yiming Onko-B (01541) quickly rose by more than 20%. As of press release, it had risen 20.27% to HK$17.8, with a turnover of HK$3.31 million.
According to the news, the company will hold a board meeting on March 25, 2024 (Monday) to consider and approve the results and publication of the company and its subsidiaries for the year ended 31 December 2023, and consider recommending payment of a final dividend (if any).
It is worth noting that the company's stock price fluctuated abnormally on March 7 and March 8. Yiming Enke announced that it was unaware of any reason for the share price fluctuation, and confirmed that the Group's business operations and clinical development remained normal, and that there were no significant adverse changes in the financial situation. Furthermore, the last day of the six-month ban period for cornerstone investors participating in the global sale of the company's shares is March 4. According to the directors' reasonable inquiries, Cornerstone investors are still full of confidence in the Group's future development and prospects.